| Autor: |
Carlos Minguito-Carazo, Julio Echarte-Morales, Tomás Benito-González, Samuel del Castillo-García, Miguel Rodríguez-Santamarta, Enrique Sánchez-Muñoz, Clea González Maniega, Rubén García-Bergel, Paula Menéndez-Suárez, Silvia Prieto-González, Carmen Palacios-Echavarren, Javier Borrego-Rodríguez, Guisela Flores-Vergara, Ignacio Iglesias-Garriz, Felipe Fernández-Vázquez |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Global Heart, Vol 16, Iss 1 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2211-8179 |
| DOI: |
10.5334/gh.916 |
| Popis: |
Background: QTc prolongation is an adverse effect of COVID-19 therapies. The use of a handheld device in this scenario has not been addressed. Objectives: To evaluate the feasibility of QTc monitoring with a smart device in COVID-19 patients receiving QTc-interfering therapies. Methods: Prospective study of consecutive COVID-19 patients treated with hydroxychloroquine ± azithromycin ± lopinavir-ritonavir. ECG monitoring was performed with 12-lead ECG or with KardiaMobile-6L. Both registries were also sequentially obtained in a cohort of healthy patients. We evaluated differences in QTc in COVID-19 patients between three different monitoring strategies: 12-lead ECG at baseline and follow-up (A), 12-lead ECG at baseline and follow-up with the smart device (B), and fully monitored with handheld 6-lead ECG (group C). Time needed to obtain an ECG registry was also documented. Results: One hundred and eighty-two COVID-19 patients were included (A: 119(65.4%); B: 50(27.5%); C: 13(7.1%). QTc peak during hospitalization did significantly increase in all groups. No differences were observed between the three monitoring strategies in QTc prolongation (p = 0.864). In the control group, all but one ECG registry with the smart device allowed QTc measurement and mean QTc did not differ between both techniques (p = 0.612), displaying a moderate reliability (ICC 0.56 [0.19–0.76]). Time of ECG registry was significantly longer for the 12-lead ECG than for handheld device in both cohorts (p < 0.001). Conclusion: QTc monitoring with KardiaMobile-6L in COVID-19 patients was feasible. Time of ECG registration was significantly lower with the smart device, which may offer an important advantage for prevention of virus dissemination among healthcare providers. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
